A marine microbiome antifungal targets urgent-threat drug-resistant fungi

Fan Zhang, Miao Zhao, Doug R Braun, Spencer S Ericksen, Jeff S Piotrowski, Justin Nelson, Jian Peng, Gene E Ananiev, Shaurya Chanana, Kenneth Barns, Jen Fossen, Hiram Sanchez, Marc G Chevrette, Ilia A Guzei, Changgui Zhao, Le Guo, Weiping Tang, Cameron R Currie, Scott R Rajski, Anjon AudhyaDavid R Andes, Tim S Bugni

Research output: Contribution to journalArticlepeer-review

Abstract

New antifungal drugs are urgently needed to address the emergence and transcontinental spread of fungal infectious diseases, such as pandrug-resistant Candida auris. Leveraging the microbiomes of marine animals and cutting-edge metabolomics and genomic tools, we identified encouraging lead antifungal molecules with in vivo efficacy. The most promising lead, turbinmicin, displays potent in vitro and mouse-model efficacy toward multiple-drug-resistant fungal pathogens, exhibits a wide safety index, and functions through a fungal-specific mode of action, targeting Sec14 of the vesicular trafficking pathway. The efficacy, safety, and mode of action distinct from other antifungal drugs make turbinmicin a highly promising antifungal drug lead to help address devastating global fungal pathogens such as C. auris.

Original languageEnglish (US)
Pages (from-to)974-978
Number of pages5
JournalScience (New York, N.Y.)
Volume370
Issue number6519
DOIs
StatePublished - Nov 20 2020

Fingerprint Dive into the research topics of 'A marine microbiome antifungal targets urgent-threat drug-resistant fungi'. Together they form a unique fingerprint.

Cite this